Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1590/0004-282X20200056 http://scihub22266oqcxt.onion/10.1590/0004-282X20200056 32609290!ä!32609290 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 259.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 259.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 259.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 259.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arq+Neuropsiquiatr 2020 ; 78 (7): 430-439 Nephropedia Template TP {{tp|p=32609290|t=2020. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach |pdf=|usr=}}{{32609290}} gab.com Text Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach JO: Arq Neuropsiquiatr http://www.kidney.de/pget.php?&tw=1&pmid=32609290 #FOAvip BACKGROUND: The novel coronavirus disease 2019 (COVID-19) pandemic poses a potential threat to patients with autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Such patients are usually treated with immunomodulatory or immunosuppressive agents, which may tamper with the organism's normal response to infections. Currently, no consensus has been reached on how to manage MS and NMOSD patients during the pandemic. OBJECTIVE: To discuss strategies to manage those patients. METHODS: We focus on how to 1) reduce COVID-19 infection risk, such as social distancing, telemedicine, and wider interval between laboratory testing/imaging; 2) manage relapses, such as avoiding treatment of mild relapse and using oral steroids; 3) manage disease-modifying therapies, such as preference for drugs associated with lower infection risk (interferons, glatiramer, teriflunomide, and natalizumab) and extended-interval dosing of natalizumab, when safe; 4) individualize the chosen MS induction-therapy (anti-CD20 monoclonal antibodies, alemtuzumab, and cladribine); 5) manage NMOSD preventive therapies, including initial therapy selection and current treatment maintenance; 6) manage MS/NMOSD patients infected with COVID-19. CONCLUSIONS: In the future, real-world case series of MS/NMOSD patients infected with COVID-19 will help us define the best management strategies. For the time being, we rely on expert experience and guidance. Twit Text FOAVip Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach ????Arq Neuropsiquiatr http://www.kidney.de/pget.php?&tw=1&pmid=32609290 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32609290 #FOAvip English Wikipedia <ref>{{Cite pmid|32609290}}</ref> Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach #MMPMID32609290 ApOstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D Arq Neuropsiquiatr 2020[Jul]; 78 (7): 430-439 PMID32609290show ga BACKGROUND: The novel coronavirus disease 2019 (COVID-19) pandemic poses a potential threat to patients with autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Such patients are usually treated with immunomodulatory or immunosuppressive agents, which may tamper with the organism's normal response to infections. Currently, no consensus has been reached on how to manage MS and NMOSD patients during the pandemic. OBJECTIVE: To discuss strategies to manage those patients. METHODS: We focus on how to 1) reduce COVID-19 infection risk, such as social distancing, telemedicine, and wider interval between laboratory testing/imaging; 2) manage relapses, such as avoiding treatment of mild relapse and using oral steroids; 3) manage disease-modifying therapies, such as preference for drugs associated with lower infection risk (interferons, glatiramer, teriflunomide, and natalizumab) and extended-interval dosing of natalizumab, when safe; 4) individualize the chosen MS induction-therapy (anti-CD20 monoclonal antibodies, alemtuzumab, and cladribine); 5) manage NMOSD preventive therapies, including initial therapy selection and current treatment maintenance; 6) manage MS/NMOSD patients infected with COVID-19. CONCLUSIONS: In the future, real-world case series of MS/NMOSD patients infected with COVID-19 will help us define the best management strategies. For the time being, we rely on expert experience and guidance. |*Coronavirus[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |China/epidemiology[MESH] |Coronavirus Infections/epidemiology/*prevention & control[MESH] |Disease Susceptibility[MESH] |Humans[MESH] |Immunologic Factors/therapeutic use[MESH] |Immunosuppressive Agents/*therapeutic use[MESH] |Infectious Disease Transmission, Patient-to-Professional/prevention & control[MESH] |Infectious Disease Transmission, Professional-to-Patient/prevention & control[MESH] |Multiple Sclerosis/diagnosis/*drug therapy[MESH] |Neuromyelitis Optica/diagnosis/*drug therapy[MESH] |Pandemics[MESH] |Pneumonia, Viral/epidemiology/*prevention & control[MESH] |Risk[MESH] |SARS-CoV-2[MESH]Management of central nervous system demyelinating diseases during the(epmc).pdf DeepDyve Pubget Overpricing